The relation between hormone receptor status and disease-free survival in adjuvant breast cancer: A multivariate analysis

e12028 Background: iPS cell inducing factors (Oct3/4, Sox2, Klf4, c-Myc, and Nanog ) are reported that they appears not only in ES cells(Embryonic stem cell), but also in normal cell or carcinoma cell, including breast carcinoma. We evaluated the expression of iPS inducing factors in the human breast cancer specimen with immunohistochemistry, and analyze the relativity of the relapse and the prognosis after the operation. Methods: 200 cases of breast cancer that were performed the surgical operation in this department were examined. Expression of c-MYC, KLF4, NANOG, OCT4 and SOX2 were determined by immunohistochemistry using a tissue microarray. Results: The average of the patient's age was 55.2 years old (29 - 87), and the advanced breast cancers in stage II or more were 122 cases (61%). About the hormone receptor and the HER2 appearance, Hormone receptor positively (HR+) types were 162 cases (81%), 10 cases (5%) were HER2 positively (HER2+) type, and 28 cases (14%) were triple negative (TN) type. During the following period from operation, the relapse was found in 48 cases (24%), and 18 cases (9%) were died. The average of survival time after the operation was 80.7 months (4 - 162). Patients with strong expression of NANOG had significantly lower disease-free survival and overall survival rates than those with weak expression of NANOG (p=0.004 and P=0.033, respectively). In contrast, patients with strong expression of KLF4 had better disease-free survival (p=0.014). Conclusions: Strong expression of NANOG was an indicator of a poor prognosis for breast cancer patients, while KLF4 was a favorable prognostic indicator. Our results suggest that NANOG stimulates the growth and metastasis of breast cancer cells, whereas KLF4 inhibits these processes.

Download Full-text

The influence of iPS-inducing factors NANOG and KLF4 in the prognosis of patients with breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.27_suppl.230 ◽

2011 ◽

Vol 29 (27_suppl) ◽

pp. 230-230 ◽

Cited By ~ 1

Author(s):

T. Nagata

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Es Cells ◽

Disease Free Survival ◽

High Expression ◽

Free Survival ◽

High Expression Group ◽

Inducing Factors ◽

Disease Free ◽

Low Expression

230 Background: iPS cell-inducing factors (Oct3/4, Sox2, Klf4, c-Myc, and Nanog) are reported that they appears not only in ES cells (embryonic stem cell), but also in normal cell or carcinoma cell, including breast carcinoma. We evaluated the expression of iPS inducing factors in the human breast cancer specimen with immunohistochemistry, and analyze the relativity of the relapse and the prognosis after the operation. Methods: 66 cases of breast cancer that were performed the surgical operation in this department were examined. Expression of c-MYC, KLF4, NANOG, OCT4, and SOX2 were determined by immunohistochemistry of tissue microarray. Results: The average of the patient’s age was 56.4 years old (36-87), and the advanced breast cancers in stage 2 or more were 44 cases (66%). About the hormone receptor and the HER2 appearance, hormone receptor-positive (HR+) types were 53 cases (80%), 6 cases (9%) were HER2-positive (HER2+) type, and 7 cases (11%) were triple-negative (TN) type. During the following period from operation, the relapse was found in 16 cases (24%), and six cases (9%) died. The average of survival time after the operation was 80.7 months (4-162). Patients with high expression group of NANOG had poor disease-free survival (p = 0.045) and overall survival (p < 0.0001) than those with low expression group. On the other hand, patients with high expression group of KLF4 had better disease-free survival (p = 0.028) than low expression group. Conclusions: High expression of NANOG was prognostic factor, but KLF4 was inversely related to prognosis in breast cancer patients. It was suggested that NANOG increased the growth and metastatic activities of breast cancer cells, while KLF4 decreased these activities.

Download Full-text

Outcomes of Adjuvant Endocrine Therapy and Hormone Receptor Status Change following Neoadjuvant Chemotherapy in Breast Cancer Patients

The International Journal of Biological Markers ◽

10.5301/jbm.5000113 ◽

2014 ◽

Vol 29 (4) ◽

pp. 380-386

Author(s):

Jia Yi Wu ◽

Wei Guo Chen ◽

Xiao Song Chen ◽

Ou Huang ◽

Jian Rong He ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Status Change ◽

Free Survival ◽

Disease Free

Background This retrospective study investigated the therapeutic benefit of adjuvant endocrine therapy (ET) in breast cancer patients with hormone receptor (HR) status change from positive to negative after neoadjuvant chemotherapy (NAC). Methods From December 2000 to November 2010, 97 eligible patients with a positive-to-negative switch of HR status after NAC were identified. All patients were categorized into 2 groups on the basis of the administration of ET: 57 ET-administered patients and 40 ET-naïve patients. Survival analyses were performed to examine the prognostic value of ET administration as well as other clinical and pathologic variables. Results The administration of ET was significantly associated with improved disease-free survival (p=0.018) in patients with a positive-to-negative switch of HR status. The 5-year disease-free survival rates were 77.0% and 55.5%, respectively, in ET-administered patients and ET-naïve patients. The 5-year overall survival rate for ET-administered patients was also higher than that of ET-naïve patients (81.3% vs. 72.7%, p=0.053), albeit this was statistically insignificant. Conclusions This study revealed that patients with HR altered from positive to negative after NAC still benefit from ET. The HR status should be evaluated not only in specimens obtained during post-NAC surgery but also in specimens biopsied before NAC.

Download Full-text

Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djj415 ◽

2006 ◽

Vol 98 (21) ◽

pp. 1571-1581 ◽

Cited By ~ 107

Author(s):

Meredith M. Regan ◽

Giuseppe Viale ◽

Mauro G. Mastropasqua ◽

Eugenio Maiorano ◽

Rastko Golouh ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Hormone Receptor Status ◽

Receptor Status ◽

Adjuvant Breast Cancer ◽

Cancer Trials

Download Full-text

Hormone Receptors and Age Distribution in Breast Cancer Patients at a University Hospital in Northern Egypt

Breast Cancer Basic and Clinical Research ◽

10.4137/bcbcr.s12214 ◽

2013 ◽

Vol 7 ◽

pp. BCBCR.S12214 ◽

Cited By ~ 2

Author(s):

Osama Hussein ◽

Mahmoud Mosbah ◽

Omar Farouk ◽

Kamel Farag ◽

Aiman El-Saed ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptors ◽

Nile Delta ◽

Age Distribution ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Receptor Status ◽

Egyptian Women ◽

Disease Free

Introduction Breast cancer is the most common cancer among Egyptian women. The disease is often advanced at diagnosis. Since molecular profiling is not feasible in routine practice, we sought to examine the association of age distribution with hormone receptor profile, disease stage and outcome among Egyptian women. Patients and Methods We conducted a retrospective review of breast cancer patients treated at Mansoura University Cancer Center in the Nile Delta from 2006 through 2011. Age groups were examined in relation to hormone receptors status and tumor clinicopathological criteria. Additionally, the effect of receptor status on disease relapse and disease-free survival was examined with logistic regression and Kaplan–Meier analysis. Results A total of 263 patients were included in the current analysis. About 66.9% (n = 176) of patients were hormone receptor positive, 14.1% (n = 37) were Her2/neu positive, and 19.0% (n = 50) were triple negative. Median age of the patients was 52 years and was equal across all receptor status types. Triple negative status correlated with increased risk of disease relapse (odds ratio = 1.8, P = 0.03) and with shortened disease-free survival (hazards ratio = 2.6, P < 0.01). Conclusion The age distribution and receptor status pattern in the Nile Delta region does not explain the aggressive behavior of the disease. The age of the patients at diagnosis is older than patients in earlier studies from Egypt emphasizing the importance of implementing mammographic screening programs.

Download Full-text